Authors: | Suarez-Almazor, M. E.; Pundole, X.; Abdel-Wahab, N.; Johnson, D. B.; Gupta, D.; Glezerman, I.; Cooksley, T.; Anderson, R.; Blidner, A.; Choi, J.; Dougan, M.; Ginex, P.; Girotra, M.; Shannon, V. R.; Rapoport, B. L. |
Review Title: | Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-mediated cardiovascular, rheumatic, and renal toxicities from checkpoint inhibitors |
Abstract: | Immune checkpoint inhibitors (ICIs) have emerged as the newest pillar of cancer treatment. Immune-mediated toxicities, stemming from increased activity within the T cell lineage, range from asymptomatic or mild complications to those that are fulminant and potentially fatal. Although they are of variable occurrence, cardiovascular, rheumatic, and renal immune-mediated toxicities are among the most serious of these adverse events. We present MASCC recommendations with respect to the workup and management of cardiovascular, rheumatic, and renal immune-mediated toxicities with a focus on presentations that require treatment with immunomodulating agents. © 2020, Springer-Verlag GmbH Germany, part of Springer Nature. |
Keywords: | arthralgia; arthritis; cardiomyopathy; myositis; corticosteroids; myocarditis; immunomodulation agents; other immunosuppressive agents; polymyalgia |
Journal Title: | Supportive Care in Cancer |
Volume: | 28 |
Issue: | 12 |
ISSN: | 0941-4355 |
Publisher: | Springer Verlag |
Date Published: | 2020-12-01 |
Start Page: | 6159 |
End Page: | 6173 |
Language: | English |
DOI: | 10.1007/s00520-020-05710-8 |
PUBMED: | 32856212 |
PROVIDER: | scopus |
DOI/URL: | |
Notes: | Article -- Export Date: 1 December 2020 -- Source: Scopus |